Loading company…
Prudentia Sciences provides AI-driven asset diligence and valuation tools for the biopharma industry.
Prudentia Sciences combines AI and human expertise to assess and value drug assets for biopharma companies and investors. Its platform is intended to support drug pipeline and capital allocation decisions. Founded in 2023, the company is based in Cambridge, US. In January 2026, it raised USD 20 million in Series A funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in